Hypertension: A Companion to Braunwald's Heart Disease
Format: PDF / Kindle (mobi) / ePub
Effectively manage the chronic problems of your hypertensive patients with the practical clinical tools inside Hypertension, 2nd Edition: A Companion to Braunwald’s Heart Disease. This respected cardiology reference covers everything you need to know - from epidemiology and pathophysiology through diagnosis, risk stratification, treatment, outcome studies, concomitant diseases, special populations and special situations, and future treatments.
- Confidently meet the needs of special populations
- Learn new methods of aggressive patient management and disease prevention
- Benefit from the authors’ Clinical Pearls
with chronic hypertensive disease, as well as hypertension and concomitant disease.
to help ensure minimal risk of further cardiovascular problems.
to reduce complications of hypertension.
- Use new combination drug therapies
- Successfully employ behavior management
and other forms of treatment to their greatest advantage in the management of chronic complications of hypertension.
as a vital part of the treatment plan for hypertensives and pre-hypertensives.
proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244-252.) history of ESRD. The three largest data sources are the screenees for the Multiple Risk Factor Intervention Trial (MRFIT), the Hypertension Clinics in the U.S. Department of Veterans Affairs Medical System, and a report from a large health maintenance organization. All three datasets show an impressive correlation of both SBP and DBP with the future risk of ESRD.54-56 In
9. Effects on prejunctional β-receptors: reduction in norepinephrine release 10. Attenuation of pressor response to catecholamines with exercise and stress Updated from Frishman WH, Silverman R: Physiologic and metabolic effects. In: Frishman WH: Clinical Pharmacology of the β-Adrenoceptor Blocking Drugs. Norwalk, CT: Appleton-Century-Crofts; 1984:28. Extended-release formulations of metoprolol and propranolol are available that allow once-daily dosing of these drugs. Both long-acting
Reactive oxygen species, NADPH oxidases, and hypertension. Hypertension. 2010;56:325-330.) also play an important role in the hypertrophic response to Ang II, because stable transfection of VSMCs with antisense to p22phox inhibits Ang II–stimulated protein synthesis. Other vasculotoxic responses to Ang II that are triggered by activation of NADPH oxidase include the oxidation of low-density lipoprotein cholesterol and increased mRNA expression for monocyte chemoattractant protein-1 (MCP-1) and
renal disease (dialysis or kidney transplantation), which has the highest annualized per-patient cost of any program supported by the Centers for Medicare and Medicaid Services. Although diabetes has typically ranked first among single “causes” of dialysis for about 25 years, hypertension has ranked second for about the same time, and, when more than one cause was allowed to be cited, hypertension was either the primary or a secondary cause of end-stage renal disease in 72% of those who began
home BP can replace ABPM for identifying individuals who have an exaggerated WCE. Stergiou and associates35 examined this issue in 189 hypertensive patients. The average WCE was the same by both home and ambulatory criteria, and the two methods gave moderately good correlations (0.64/0.59); however, on an individual basis, for the identification of an exaggerated WCE (defined as >20/10 mm Hg), the agreement was not so close. Of the 189 patients, 164 (87%) were classified the same (for systolic